Linda X Yin1, Gypsyamber D'Souza2, William H Westra3, Steven J Wang4, Annemieke van Zante5, Yuehan Zhang2, Eleni M Rettig6, William R Ryan7, Patrick K Ha7, Alicia Wentz2, Wayne Koch6, David W Eisele6, Carole Fakhry6. 1. Department of Otorhinolaryngology, Mayo Clinic, Rochester, Minnesota. 2. Department of Epidemiology, Johns Hopkins University, Baltimore, Maryland. 3. Department of Pathology, Johns Hopkins University, Baltimore, Maryland. 4. Department of Otolaryngology-Head and Neck Surgery, University of Arizona, Tucson, Arizona. 5. Department of Pathology, University of California-San Francisco, San Francisco, California, U.S.A. 6. Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University, Baltimore, Maryland. 7. Department of Otolaryngology-Head and Neck Surgery, University of California-San Francisco, San Francisco, California, U.S.A.
Abstract
OBJECTIVES/HYPOTHESIS: Human papillomavirus (HPV)-positive and HPV-negative oropharyngeal squamous cell carcinoma (OPSCC) are distinct disease entities. Prognostic factors specific to each entity have not been adequately explored. Goals for this study were: 1) to determine whether HPV-positive and HPV-negative OPSCCs have distinct prognostic factors, and 2) to explore the prognostic significance of sex and race in OPSCC after HPV stratification STUDY DESIGN: Retrospective case series. METHODS: A retrospective review of 239 incident OPSCC patients from 1995 to 2012, treated at Johns Hopkins and University of California-San Francisco was conducted. Women and nonwhite races were oversampled. All analyses were stratified by tumor HPV in situ hybridization status. The effects of sex and race on survival were considered in Kaplan-Meier and unadjusted and adjusted Cox regression models. RESULTS: One hundred thirty-four (56.1%) OPSCC patients were HPV positive. On univariate analysis, women had better overall survival than men among HPV-positive (hazard ratio [HR]: 0.47, 95% confidence interval [CI]: 0.20-1.07; P = .06) but not HPV-negative (HR: 0.73, 95% CI: 0.43-1.24; P = .24) OPSCCs. On multivariate analysis, women with HPV-positive OPSCCs remained at lower risk of death (adjusted hazard ratio [aHR]: 0.34, 95% CI: 0.12-0.96; P = .04). Survival did not vary significantly by race among HPV-positive patients. Among HPV-negative patients, Hispanic patients had significantly better survival in unadjusted (HR: 0.27, 95% CI: 0.08-0.91; P = .04) but not adjusted (aHR: 0.93, 95% CI: 0.11-7.36; P = .94) analysis. CONCLUSIONS: Women with HPV-positive OPSCC may have improved overall survival compared to men. Sex does not play a prognostic role in HPV-negative OPSCC. There are no differences in prognosis by race among HPV-positive or HPV-negative patients. LEVEL OF EVIDENCE: 4 Laryngoscope, E287-E295, 2018.
OBJECTIVES/HYPOTHESIS: Human papillomavirus (HPV)-positive and HPV-negative oropharyngeal squamous cell carcinoma (OPSCC) are distinct disease entities. Prognostic factors specific to each entity have not been adequately explored. Goals for this study were: 1) to determine whether HPV-positive and HPV-negative OPSCCs have distinct prognostic factors, and 2) to explore the prognostic significance of sex and race in OPSCC after HPV stratification STUDY DESIGN: Retrospective case series. METHODS: A retrospective review of 239 incident OPSCC patients from 1995 to 2012, treated at Johns Hopkins and University of California-San Francisco was conducted. Women and nonwhite races were oversampled. All analyses were stratified by tumor HPV in situ hybridization status. The effects of sex and race on survival were considered in Kaplan-Meier and unadjusted and adjusted Cox regression models. RESULTS: One hundred thirty-four (56.1%) OPSCC patients were HPV positive. On univariate analysis, women had better overall survival than men among HPV-positive (hazard ratio [HR]: 0.47, 95% confidence interval [CI]: 0.20-1.07; P = .06) but not HPV-negative (HR: 0.73, 95% CI: 0.43-1.24; P = .24) OPSCCs. On multivariate analysis, women with HPV-positive OPSCCs remained at lower risk of death (adjusted hazard ratio [aHR]: 0.34, 95% CI: 0.12-0.96; P = .04). Survival did not vary significantly by race among HPV-positive patients. Among HPV-negative patients, Hispanic patients had significantly better survival in unadjusted (HR: 0.27, 95% CI: 0.08-0.91; P = .04) but not adjusted (aHR: 0.93, 95% CI: 0.11-7.36; P = .94) analysis. CONCLUSIONS: Women with HPV-positive OPSCC may have improved overall survival compared to men. Sex does not play a prognostic role in HPV-negative OPSCC. There are no differences in prognosis by race among HPV-positive or HPV-negative patients. LEVEL OF EVIDENCE: 4 Laryngoscope, E287-E295, 2018.
Authors: Dan P Zandberg; Sandy Liu; Olga Goloubeva; Robert Ord; Scott E Strome; Mohan Suntharalingam; Rodney Taylor; Robert E Morales; Jeffrey S Wolf; Ann Zimrin; Joshua E Lubek; Lisa M Schumaker; Kevin J Cullen Journal: Head Neck Date: 2015-06-30 Impact factor: 3.147
Authors: Mira A Patel; Amanda L Blackford; Eleni M Rettig; Jeremy D Richmon; David W Eisele; Carole Fakhry Journal: Cancer Date: 2016-03-07 Impact factor: 6.860
Authors: A M Hong; T A Dobbins; C S Lee; D Jones; G B Harnett; B K Armstrong; J R Clark; C G Milross; J Kim; C J O'Brien; B R Rose Journal: Br J Cancer Date: 2010-10-19 Impact factor: 7.640
Authors: Kathleen Settle; Marshall R Posner; Lisa M Schumaker; Ming Tan; Mohan Suntharalingam; Olga Goloubeva; Scott E Strome; Robert I Haddad; Shital S Patel; Earl V Cambell; Nicholas Sarlis; Jochen Lorch; Kevin J Cullen Journal: Cancer Prev Res (Phila) Date: 2009-07-29
Authors: A Argiris; S Li; M Ghebremichael; A M Egloff; L Wang; A A Forastiere; B Burtness; R Mehra Journal: Ann Oncol Date: 2014-05-05 Impact factor: 32.976
Authors: Carole Fakhry; Tim Waterboer; William H Westra; Lisa M Rooper; Melina Windon; Tanya Troy; Wayne Koch; Christine G Gourin; Noemi Bender; Siddhartha Yavvari; Ana P Kiess; Brett A Miles; William R Ryan; Patrick K Ha; David W Eisele; Gypsyamber D'Souza Journal: Oral Oncol Date: 2019-12-24 Impact factor: 5.337
Authors: Derek D Kao; Rocco M Ferrandino; Deborah C Marshall; Tinaye Mutetwa; Brett Miles; Joshua M Bauml; Keith M Sigel Journal: Int J Otolaryngol Date: 2022-05-02
Authors: Alhadi Almangush; Lauri Jouhi; Timo Atula; Caj Haglund; Antti A Mäkitie; Jaana Hagström; Ilmo Leivo Journal: Br J Cancer Date: 2022-01-18 Impact factor: 9.075